HBOT Conversations:
Robert Beckman & NBIRR Study
Robert Beckman, Ph.D., Founder of the TreatNow Coalition in Arlington, Virginia, discusses the National Brain Injury Rescue Rehabilitation study focused on the use of Hyperbaric Oxygen Therapy for brain injuries. Beckman has a passion for data and helping veterans, which is what ultimately got him first involved in Hyperbaric Oxygen Therapy back in 2008. He was one of many, participating with an elite group of doctors and HBOT experts, who organized and oversaw the results of NBIRR, a multi-center HBOT trial for mild traumatic brain injury with post-concussive symptoms.
The TreatNow Coalition’s Mission is to Stop service member suicides by identifying and treating veterans and others suffering from brain wounds, TBI, PTSD, and Concussion.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with guest, Robert Beckman, founder of Treatnow.org, who was instrumental in the compilation and release of The National Brain Injury Rescue and Rehabilitation Study – a multicenter observational study of hyperbaric oxygen for mild traumatic brain injury with post-concussive symptoms.
It took over a decade for that study to be completed and published. Once it was, it not only opened a door for veterans and others who were looking for a way to heal from head trauma, the NBIRR study ignited other studies to start, focusing solely on the safety & efficacy of Hyperbaric Oxygen Therapy for brain injuries.
Beckman discusses some of the challenges he has witnessed over the years, including the Army declaring that HBOT does not work. After combing through the data, Beckman states that their analysis is rooted in a “lie” about the sham they used in their study; everyone got better. This starts an in-depth conversation between di Girolamo and Beckman about the frustration of the government so easily dismissing HBOT, inflammation linked to PTSD, the stigma of PTSD being a personal and not a physical problem, the disappointment that most veterans don’t even know HBOT exists, and why more is not being done to heal our veterans from these invisible injuries of war.
Beckman proudly states that what started as nine clinics to treat veterans under the NBIRR study, has grown to about 135 clinics across the country that specialize in treating veterans with HBOT for free or reduced rates. Additionally, there are now a combined 12,500-plus success stories from these 135 clinics of individuals with TBI, PTSD, and mTBI who have completed 40 treatments/dives.
Beckman gives surgical statistics relating to HBOT and explains that by pre-oxygenating and post-oxygenating via hyperbaric chambers, patients can benefit from a 30-40% faster healing rate. He points out that countless professional athletes are now using hyperbaric oxygen therapy for faster recuperation to treat pain, injuries, and inflammation; and hyperbarics is being used all over the world right now for successfully treating COVID long-haulers. He states that COVID long-haulers are hypoxic suffering patients, and data exists that military personnel who have experienced the blow of an IUD are suffering in much of the same manner – it’s that lack of oxygen to the brain and all parts of the suffering body that HBOT helps.
di Girolamo asks the question so many of us are curious about, “If HBOT obviously works, why isn’t the military admitting to this? Why aren’t we using it more?” Beckman suggests we read this particular blog on his website that sheds much light on the subject, The Obvious Question: If HBOT works, why aren’t we using it?
Beckman reminds di Girolamo – and all of us – that this is a marathon. Yes, they’ve made great strides over the past two decades in education and research for hyperbaric oxygen therapy, but they still have a way to go. He continues to be optimistic that one day we’ll all witness our shared goal of eliminating the suicide epidemic by utilizing HBOT to thoroughly heal brain injuries.
Guest
Robert L. Beckman, Ph.D.
Dr. Beckman has been building knowledge management systems most of his professional career, primarily in the Intelligence Community and DOD. He is currently helping to run the Clinical Trial researching TBI and PTSD in brain-injured wounded warriors. He is responsible for sustaining the national network of hyperbaric clinics as well as improving the technology platform for data collection and analysis. He is a former USAF KC-135 pilot and a Vietnam Veteran.
TreatNow.org
(571) 549-4258
beckmanr88@gmail.com
Contact TreatNow.org
https://treatnow.org/
Subscribe Now, It’s Free !
Recent HBOT News
Clinical Trial – SOFT Block Versus Spinal Anesthesia in Patientsusing Ilizarov External Fixator
Peripheral nerve block is an ideal choice for lower limb surgery because of the peripheral
site of the surgical procedure and the ability to block pain pathways at multiple levels. On
the contrary to other anesthetic techniques, as spinal or general anesthesia, properly
performed peripheral nerve blocks bypass adverse events as hemodynamic instability and
respiratory complications, properly treat post-operative pain leading to early hospital
discharge. Additional advantages of peripheral nerve blocks are that they can be used in
patients receiving anti-coagulants or lumbosacral disease in addition to avoidance of airway
instrumentation.
Recently, there has been a significant interest in regional anesthesia and peripheral nerve
blockade. This is facilitated by a significant advance of the research in this field and
availability of better equipment facilitating regional anesthesia.The aim of this study was
to assess the efficacy and safety of SOFT block (sciatic-obturator-femoral nerve block
technique) in comparison with spinal anesthesia in patients undergoing surgery for fixation
of open tibial fractures using Ilizarov external fixator.
Clinical Trial – Effect of Intrathecal Morphine on Chronic Pain After Elective Caesarean Section
The incidence of chronic post-surgical pain (CPSP) after caesarean section (CS) is reported
to be as high as 18%, reflecting it to be a significant clinical problem. Studies related to
prevention of progression of acute post-CS pain to its chronicity are sparse. Current
guidelines on post-CS analgesia recommend the use of intrathecal (IT) opioids to spinal
anaesthesia for improved post-CS pain relief. Despite its frequent use, studies related to
the IT morphine use and its association with post-CS chronic pain are lacking.
A recent prospective observation study revealed a significant reduction in persistent pain
after CS when IT morphine was used as an adjuvant to spinal anaesthesia. However, there is no
any randomized controlled trial (RCT) that has explored this association to date. We
hypothesized that spinal morphine would reduce the incidence of persistent pain after CS.
Long non-coding RNA LINC00152 promotes cell growth and invasion of papillary thyroid carcinoma by regulating the miR-497/BDNF axis.
Abstract: Long intergenic non-coding RNA 152 (LINC00152) was reported to be tightly linked to tumorigenesis and progression in multiple cancers. However, its biological role and modulatory mechanism in papillary thyroid carcinoma (PTC) has not been elucidated. In this...